慢性阻塞性肺病和气喘设备市场规模、份额和成长分析（按产品、适应症、分销管道和地区）- 产业预测 2025-2032

预计 2023 年全球 COPD 和气喘设备市场规模将达到 487.8 亿美元，并从 2024 年的 511.7 亿美元成长到 2032 年的 750.3 亿美元，预测期内（2025-2032 年）的复合年增长率为 4.9%。

由于慢性阻塞性肺病(COPD) 和气喘的盛行率不断上升、技术进步以及老年人口的不断增加，肺部药物输送装置市场正在成长。慢性阻塞性肺病的特征是气流阻塞，症状包括呼吸短促和慢性咳嗽，而气喘的特征是气道功能下降和呼吸困难，需要有效的吸入疗法。这些设备将液体药物转化为气溶胶颗粒，确保有针对性地输送以控制这些慢性病。随着医疗保健提供者寻求创新方法来支持不断增长的患者群体，气喘患者数量的急剧增加和对有效管理解决方案的需求正在推动市场增长，凸显了这些治疗设备在呼吸护理中的重要性。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和资料资料
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

COPD 和气喘设备市场规模（按产品和复合年增长率） (2025-2032)

• 市场概况
• 吸入器
  • 药物粉末吸入器 (DPI)
  • 定量喷雾吸入器(MDI)
  • 缓雾吸入器
• 喷雾器
  • 压缩机雾化器
  • 超音波雾化器
  • 网状雾化器

COPD 和气喘设备市场规模（按适应症和复合年增长率）（2025-2032）

• 市场概况
• 气喘
• 慢性阻塞性肺病

COPD 和气喘设备市场规模（按分销管道和复合年增长率）（2025-2032）

• 市场概况
• 零售药局
• 医院
• 网路药局

慢性阻塞性肺病及气喘设备市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较（2022-2024 年）

主要企业简介

• AstraZeneca Plc.（United Kingdom）
• GlaxoSmithKline Plc.（United Kingdom）
• Merck & Co., Inc.（United States）
• Novartis AG（Switzerland）
• 3M Company（United States）
• Baxter International Inc.（United States）
• ResMed Inc.（United States）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Cipla Ltd.（India）
• Omron Healthcare, Inc.（Japan）
• Invacare Corporation（United States）
• Masimo Corporation（United States）
• Nihon Kohden Corporation（Japan）
• Getinge AB（Sweden）
• Smiths Medical（United Kingdom）
• Allied Healthcare Products, Inc.（United States）
• Aerogen Ltd.（Ireland）
• PARI Medical Holding GmbH（Germany）

结论和建议

Global COPD and Asthma Devices Market size was valued at USD 48.78 billion in 2023 and is poised to grow from USD 51.17 billion in 2024 to USD 75.03 billion by 2032, growing at a CAGR of 4.9% during the forecast period (2025-2032).

The market for pulmonary medication delivery devices is on the rise, driven by the increasing prevalence of chronic obstructive pulmonary disease (COPD) and asthma, as well as technological advancements and a growing elderly population. COPD, characterized by airflow blockage and symptoms like shortness of breath and chronic cough, and asthma, marked by compromised airway function and respiratory distress, necessitate effective inhalation therapies. These devices transform drug solutions into aerosolized particles, ensuring targeted delivery for managing these chronic conditions. The surge in asthma cases and the need for effective management solutions are propelling market growth, as healthcare providers seek innovative ways to support a rising patient population, underlining the importance of these therapeutic devices in respiratory care.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Copd And Asthma Devices market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global COPD And Asthma Devices Market Segmental Analysis

Global COPD and Asthma Devices Market is segmented by Product, Indication, Distribution Channel and region. Based on Product, the market is segmented into Inhalers and Nebulizers. Based on Indication, the market is segmented into Asthma and COPD. Based on Distribution Channel, the market is segmented into Retail Pharmacies, Hospitals and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global COPD And Asthma Devices Market

The global market for COPD and asthma devices is driven by the increasing incidence of various respiratory conditions such as COPD, asthma, and emphysema. There is an escalating demand for effective short-term treatments and rescue medications, particularly during sudden asthma attacks. Furthermore, government initiatives aimed at enhancing awareness of COPD and asthma symptoms, alongside manufacturers' efforts to innovate portable inhalation devices, are expected to contribute to market growth. As respiratory illnesses lead to significant health complications, the advancement of technology in inhalation devices plays a crucial role in addressing these challenges, facilitating both immediate relief and long-term management solutions for affected individuals.

Restraints in the Global COPD And Asthma Devices Market

The global market for COPD and asthma devices faces several restraints that may hinder its growth. Significant factors include the high cost associated with various inhalation devices and treatments, which can limit accessibility for patients. Environmental concerns regarding metered dose inhalers (MDI) also pose challenges. Furthermore, intense price competition among manufacturers can affect profit margins, while declining material quality may compromise the effectiveness of devices. Limited reimbursement options additionally exacerbate the situation, along with the patent expirations of highly profitable medications, creating hurdles for the sustained expansion of the market.

Market Trends of the Global COPD And Asthma Devices Market

The global COPD and asthma devices market is experiencing a significant shift towards digital inhalers, presenting substantial opportunities for clinical pharmacy. These innovative devices not only enable precise delivery of medication directly to the lungs, minimizing systemic side effects, but they also address persistent challenges in treatment, such as poor adherence and improper usage. As healthcare providers increasingly recognize the importance of patient compliance in managing chronic respiratory conditions, digital inhalers equipped with adherence tracking and user-friendly interfaces are gaining traction. This trend is likely to enhance treatment outcomes, reduce exacerbations, and drive market growth as patients seek more effective, technology-enabled management solutions for COPD and asthma.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global COPD and Asthma Devices Market Size by Product & CAGR (2025-2032)

• Market Overview
• Inhalers
  • Drug Powdered Inhalers (DPIs)
  • Metered Dose Inhalers (MDIs)
  • Soft Mist Inhalers
• Nebulizers
  • Compressor Nebulizers
  • Ultrasonic Nebulizers
  • Mesh Nebulizers

Global COPD and Asthma Devices Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Asthma
• COPD

Global COPD and Asthma Devices Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Retail Pharmacies
• Hospitals
• Online Pharmacies

Global COPD and Asthma Devices Market Size & CAGR (2025-2032)

• North America (Product, Indication, Distribution Channel)
  • US
  • Canada
• Europe (Product, Indication, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Indication, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Indication, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Indication, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AstraZeneca Plc. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline Plc. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• 3M Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ResMed Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Omron Healthcare, Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Invacare Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Masimo Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nihon Kohden Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Getinge AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Smiths Medical (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allied Healthcare Products, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aerogen Ltd. (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PARI Medical Holding GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations